Beta-catenin–T-cell factor interaction (β-catenin–TCF interaction)

The beta-catenin–T-cell factor (TCF) interaction is a core event in the canonical Wnt signaling pathway, critical for the regulation of gene transcription in response to Wnt ligand stimulation. In the absence of Wnt, TCF/LEF family transcription factors (including TCF1, TCF3, TCF4, and LEF1) act as repressors by binding DNA and recruiting co-repressors such as Groucho/TLE, keeping Wnt target genes inactive. Upon Wnt activation, cytoplasmic β-catenin is stabilized and accumulates in the nucleus, where it binds to TCF/LEF transcription factors. The β-catenin–TCF complex acts as a transcriptional co-activator, displacing repressors and initiating target gene transcription that drives cell proliferation, differentiation, and stem cell fate decisions. Aberrant activation of this complex drives tumorigenesis, particularly in colorectal and other cancers, making this interaction an important therapeutic target. Several small-molecule inhibitors are in development to disrupt this interaction, but balancing efficacy with on-target toxicity to normal tissue remains a challenge[1][2][3][4][5][6][8].

Other names

Beta-catenin–TCF complexBeta-catenin–LEF/TCF complexβ-catenin–TCF/LEF complexβ-catenin–Lef/Tcf interactionWnt/β-catenin–TCF complex

Disruption of β-catenin–TCF interaction: Drugs bind to β-catenin or TCF to prevent complex formation, suppressing Wnt target gene transcription; Inhibition of nuclear transactivation: Preventing recruitment of transcriptional coactivators (like CBP/p300) needed for Wnt target genes